Richmond Appoints Dr. Lisa Campbell as Director of Regulatory Strategy

Richmond Pharmacology has appointed Dr Lisa Campbell as Director of Regulatory Strategy, strengthening its leadership in regulatory science, early-phase clinical trials, and advanced therapy development as well as Richmond’s commitment to achieving faster answers.

Lisa brings over 20 years of experience across regulatory affairs, clinical medicine, and drug development strategy. She joins Richmond from SSI Strategy, where she led global regulatory programmes and clinical development for advanced therapies, including gene therapy for rare and paediatric conditions. Previously, she served for over nine years as a Senior Medical Assessor at the MHRA, leading on first-in-human trial assessments, patient and public involvement in research, platform trial design, and regulatory responses during the COVID-19 pandemic.

In her new role, Lisa will lead Richmond’s regulatory function, providing strategic oversight on regulatory submissions, stakeholder engagement, and the development of a regulatory outsourcing service. She will also oversee the company’s medical writing team, ensuring compliance with international guidance while supporting business development and continuous improvement initiatives.

Lisa holds an MD in Diabetes in Pregnancy from the University of Wales, Cardiff, and has published extensively in journals such as Nature Medicine, BMJ Open, JAMA, and PharmaLetter.

“I’m excited to join Richmond and contribute to shaping its regulatory leadership,” said Lisa. “It’s a privilege to support research that puts scientific excellence, regulatory rigour, and patient input at the centre of everything we do.”

Lisa’s appointment reflects Richmond’s commitment to building a future-focused regulatory environment that meets the needs of trial sponsors, regulators, and – most importantly – patients.

-Ends-

Notes to Editor: 

About Richmond 

Richmond is a leading UK contract research organisation, founded in 2001, specialising in first-in-human studies and adaptive clinical trials for gene editing and gene silencing therapies. In 2021 it was first in the world to treat a patient with the Nobel Prize-winning CRISPR-cas9 gene editing tool and currently has more patients undergoing cutting-edge genetic trials than any other clinic in the world. It has completed more than 500 early phase studies and helped deliver 30 medicines to market - including drugs for heart failure, hypertension and cancer. Clients include top 10 pharma, genetic engineering and biotech companies from around the world, especially Europe, the USA and Japan. In 2020, Richmond founded the Richmond Research Institute to advance understanding of under-researched diseases. 

For more information, please contact Linda Rose: linda@denhams.digital 07788 592842